clinical trial · NCT06270836
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)
Diabetic RetinopathyTarcocimabSham injection
brief summary
This study will demonstrate that tarcocimab 5 mg is superior to sham treatment in participants with DR.
started
May 1, 2024
primary completion
Jan 31, 2026
completion
Jan 31, 2026
last updated
Mar 30, 2025
detailed description
This is a prospective, randomized, double-masked, two-arm, multi-center Phase 3 study to demonstrate that tarcocimab 5 mg is superior to sham treatment, with respect to the proportion of eyes improving from baseline at Week 48 in participants with DR.
official title
A Prospective, Randomized, Double-masked, Sham-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tarcocimab Tedromer in Participants With Diabetic Retinopathy (DR) - GLOW2
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol